Top Stories

Published on Tuesday, November 6, 2018

Mereo BioPharma and TAP work together in clinical study

Mereo BioPharma and TAP work together in clinical study

Mereo BioPharma Group plc announced a collaboration with (and investment from) the venture philanthropy arm of the Alpha-1 Foundation, The Alpha-1 Project, Inc. (TAP) in Mereo’s MPH-966 development program.

MPH-966 is an oral neutrophil elastase inhibitor that specifically targets the neutrophil elastase which is primarily responsible for the lung degradation in Alpha-1 patients.

TAP investment was announced in Mereo’s November 5th press release, publicizing that the first Alpha-1 patient was dosed in their Phase 2 clinical study of MPH-966 (alvelestat). The study is a 12-week randomized, placebo controlled, clinical trial evaluating two doses of MPH-966 in approximately 165 patients with the ZZ or NULL genetic mutations of Alpha-1. These mutations are associated with the more severely affected patients who have very low (ZZ) or zero (NULL) alpha-1 antitrypsin levels.

“We are very pleased that the first patient has been successfully dosed in this phase 2 study in Alpha-1 Antitrypsin Deficiency. We are excited by the potential for a new oral therapeutic to improve the lives of our patients with this debilitating disease and are pleased to be supporting Mereo with this phase 2 study,” said Jean-Marc Quach, president and CEO of TAP.

The study is being conducted in the United States and Europe with top line data expected in the second half of 2019. If the results are positive, Mereo intends to seek regulatory advice on the design of a pivotal trial.

To read the full press release, please click here.

Source: Mereo BioPharma Group plc


FDA grants Arrowhead orphan drug designation for potential therapy for Alpha-1 liver disease

Wednesday, June 10, 2015
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ARC-AAT, a potential therapy for Alpha-1 Antitrypsin Deficiency now being developed by Arrowhead Research Corp. of California. The “gene silencing”...

Alpha-1 Patient Assistance Advisory Council to collaborate, advise on patient assistance programs

Tuesday, June 9, 2015
The Alpha-1 Foundation and AlphaNet have formed an Alpha-1 Patient Assistance Advisory Council to make recommendations and provide guidance on patient assistance programs through collaboration with assistance administrators, specialty pharmacies,...

Mary Lyle and her "lucky" family are grateful they can help with Alpha-1 research

Wednesday, June 3, 2015
In 2010, Mary Lyle had never heard of Alpha-1 Antitrypsin Deficiency. Her story will be familiar to many Alphas: Nineteen years earlier, she had a cold that would not go away. Several doctors diagnosed her with asthma. She was treated with...

COPD Foundation hosts innovators and idea gurus to find new solutions for COPD community

Wednesday, June 3, 2015
Bestselling authors, innovation and technology gurus, artists, educators, and CEOs from various disciplines have come together "to develop new and inventive solutions that go ‘beyond the medicine’ to enhance the lives of all people...

The Lancet publishes RAPID trial results showing effectiveness of Alpha-1 augmentation therapy

Thursday, May 28, 2015
The Alpha-1 Foundation on Thursday congratulated the investigators and sponsor of the RAPID Trial, demonstrating the effectiveness of augmentation therapy in slowing emphysema due to Alpha-1 Antitrypsin Deficiency, on the publication of the trial...

TAP partner Alnylam files application in U.K. for clinical trial on treatment for Alpha-1 liver disease

Monday, May 18, 2015
Alnylam Pharmaceuticals announced Sunday that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, an injectable RNAi...

Foundation awards record $1.8 million to 2015 research grant recipients at ATS reception May 18

Thursday, May 14, 2015
The Alpha-1 Foundation announced its 2015 grant awardees on Monday, May 18, during a reception at the American Thoracic Society (ATS) International Conference in Denver. “For the first time in the program’s history, the Foundation...

Arrowhead announces good initial safety results in study of potential Alpha-1 liver disease drug

Tuesday, May 5, 2015
Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, on Tuesday announced that it completed dosing healthy volunteers and will begin dosing patients in an ongoing phase 1 study of ARC-AAT, the...

BU Alpha-1 Center Director Darrell Kotton gets $1.74 million award for new lung facility

Wednesday, April 29, 2015
The Massachusetts Life Sciences Center (MLSC) has awarded $1.74 million to Boston University’s Center for Regenerative Medicine (CReM) to help build a new lung regeneration facility. The new facility, to be housed at CReM...

BU Researchers Produce iPSC Model to Better Understand Alpha-1

Thursday, April 2, 2015
Using patient-derived stem cells known as induced pluripotent stem cells (iPSC) to study Alpha-1 Antitrypsin Deficiency, Boston University researchers have for the first time created a disease signature that may help explain how abnormal protein...

Foundation Clinical, Research Registry directors appointed to PlasmaTech Scientific Advisory Board

Wednesday, April 1, 2015
PlasmaTech Biopharmaceuticals has appointed the Alpha-1 Foundation's Clinical Director Robert Sandhaus, MD, PhD, and Research Registry Director Charlie Strange, MD, to its Scientific Advisory Board (SAB).  The SAB will serve as a...

TAP partnership to help fund study of Arrowhead liver disease treatment

Thursday, June 19, 2014
The Alpha-1 Project (TAP), the venture philanthropy subsidiary of the Alpha-1 Foundation, said Thursday it will partner with biopharmaceutical company Arrowhead Research on its next clinical candidate, ARC-AAT, an RNA interference (RNAi)...

Article Search

Enter keywords in text box and click Search button for results.